Log in to save to my catalogue

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_35465bb2f20d44ce85e4f6039cf0e079

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma

About this item

Publication information

Publisher

Basel, Switzerland: S. Karger AG

More information

Scope and Contents

Contents

Introduction: Cabozantinib has been approved by the European Medicine Agency (EMA) for hepatocellular carcinoma (HCC) previously treated with sorafenib. Cabozantinib is also being tested in combination with immune checkpoint inhibitors in the frontline setting. Real-life clinical data of cabozantinib for HCC are still lacking. Moreover, the prognos...

Alternative Titles

Full title

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_35465bb2f20d44ce85e4f6039cf0e079

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_35465bb2f20d44ce85e4f6039cf0e079

Other Identifiers

ISSN

2235-1795

E-ISSN

1664-5553

DOI

10.1159/000515551

How to access this item